The purpose of the Developmental Research Program (DRP) is to stimulate the initiation, development and implementation of innovative research within the University of Pittsburgh Skin Cancer SPORE. The UPCI has sponsored a substantial amount of developmental research in the Melanoma and Skin Cancers Program (MSCP) over the past 20 years on an ad hoc basis, as new faculty with interests in these cancers have been recruited and as compelling new research concepts or infrastructure has been required to support these efforts. As an important component of this application for a Skin Cancer SPORE, we propose to shift to a more formal and regular pilot project program.
The Specific Aims of the DRP are: 1. To stimulate the initiation of novel research concepts related to melanoma and other skin cancers, that exhibit promise for development into full, translational research projects to be sponsored prospectively by the Skin Cancer SPORE 2. To stimulate the development of existing translational research concepts that have been applied successfully to other neoplasms/diseases, but that have not yet been applied to melanoma or other skin cancers, and which would be expected to develop into full projects sponsored prospectively by the Skin Cancer SPORE 3. To facilitate the development of research that may yield full projects to be sponsored prospectively by the SPORE 4. To increase the visibility of the SPORE'S basic and clinical research activities in order to increase the participation of basic scientists on the one hand, and clinicians and patients on the other, thereby fortifying the SPORE'S research efforts We intend to utilize the SPORE DRP to complement existing funding mechanisms that are available to the scientific and clinical investigation community of the UPCI and the University of Pittsburgh at large, including the UPCI's pilot grant program, the recently initiated Hillman Foundation Fellows in Innovative Cancer Research program, the Competitive Medical Research Fund of the UPMC, and departmental research support. To accomplish these goals, $150,000 of institutional support has been committed to provide sufficient levels for funding to underwrite two concurrent DRP proposals per year (i.e., $75,000 for each project). Awards will be made for one year, with the possibility for competitive renewal for a second year, pending significant progress made during the initial period of support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-03
Application #
8129535
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
3
Fiscal Year
2010
Total Cost
$146,454
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739
Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190
Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15

Showing the most recent 10 out of 209 publications